Trial Profile
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Trastuzumab
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KATHERINE
- Sponsors Roche
- 08 Dec 2023 According to Genentech media release, Prof. Dr. Sibylle Loibl is principal investigator of this trial.
- 08 Dec 2023 According to Genentech media release, company announced positive long term follow up data from this study in being presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium on Friday, December 8.
- 08 Dec 2023 Results presented in a Genentech Media release.